Eisai Company, Ltd. Announces Launch of Antiepileptic Drug Fycompa In U.S.
Tokyo, Jan 6, 2014 - (JCN Newswire) - Eisai Co., Ltd. (Headquarters: Tokyo, President & CEO: Haruo Naito, "Eisai") announced today that on January 2, 2014, its U.S. subsidiary Eisai Inc. launched the AMPA receptor antagonist Fycompa (perampanel), a first-in-class antiepileptic drug (AED) discovered and developed In-house, in the United States as an adjunctive therapy for partial-onset seizures with or without secondary generalized seizures in patients with epilepsy aged 12 and older.
Help employers find you! Check out all the jobs and post your resume.